they couldn't keep a phase3 trial secret, and if anything they would want it public to attract recruits and investors.

Oh, you want to know more about that ? There was no clinical phase III trial yet performed. They moved over to the other compound (I think first compound was rember, the other one LMTX) because it had several advantages. So the clinical phase III is delayed. It surprises me they start a clinical phase III trial on another disease instead of on Alzheimer.

White rated myself on methylene blue for about 5 weeks. Took a suggested dosage from another site mixed with vit c and baking soda with no effect other than an upset stomach. I had no clear way to quantify the dosage and was afraid of taking too large a dose, so i kept it at no more than a diluted drop in a small glass of water. Be careful its very staining. As i purchased my blue from a pet supply co. and showed no improvement in my PD i saw no reason to continue,and became fearful i might be harming myself. Their patent might include a better way to penetrate the blood brain barrier.

from what i read today, phase 3 a global approach is soon to start...the new drug version - an updated version of rember, which I must say I have been trying to find out information on since reading about phase 2 results back in 2009.

I am aware that the TauRx website is about to update all their information and hopefully include or show a lot more of their data..but in saying this..I have also gone back one of the initial sources and been able to locate some scholarly articles from Wischick (sorry from memory as I have my notes at work) and also at the Arbedeen university...was albe to find more information regarding rember there....

I would like to think that if funding form the FDDA is forth coming then the research (and product) has to have some merit!!!!! I live in hope.......literally...

Mel

Arsippe and Soccertese

I have been following this company TauRx for some time.

There were excellent results for a really large 321-patient Phase 2 trial for Alzheimer's Disease (AD) using their first-generation drug called rember. The company then spent the last few years perfecting their 2nd-generation improved version of their drug LMTX.

From what I have gathered so far, LMTX will be used for the Phase 3 trial of FTD (FrontoTemporal Dementia), and very likely thereafter for the long-awaited Phase 3 AD trial. The TauRx team have also discovered that LMTX could also have beneficial effects on other proteins which aggregate abnormally, including TDP-43 in FTD and synuclein in Parkinson's disease so we will be seeing clinical trials on PD too. The question is when.

The fact that TauRx has announced the launch of their FTD Phase 3 trial WITHOUT any calls for further funding means that they must already have the necessary funds in place to start the process with a therapeutically focused global contract research organisation (CRO) to handle the Phase 3 trial. So clearly this is no empty hype - which we often see when companies come out with big plans and big claims to drum up investor interest.... and then ask for funding.

We can have hope. Exciting times ahead!

Certainly agree with you Mel!

JK, thank you for your careful analysis with update.

tauRx have updated certain parts of their website....they also have a frequent questions and answers sections.......
Interesting...appears that they have gone into partenership with Bayer??

Also...appears as if this trial will not mean that AD patients will have to wait for additional phase 3 trials to take place.....fingers crossed that phase 3 results are just as promissing as those of rember...... and here is hoping that a product is on the market in 2014.....if not earlier.....and available worldwide with no red tape.......

I had posted this earlier under the Alzheimer's thread, but thought it relevant to post this here too as this thread discussed how LMTX can also work on Parkinsons....

A recap on "rember" : Data released in 2008 from Phase II trials involving 321 patients with mild and moderate Alzheimer’s disease revealed a 80% - 90% reduction in the rate of disease progression over two years in mild-moderate Alzheimer’s patients.

Well, the improved second generation rember is called LMTX and this is about to go into Phase 3 clinical trials!

Saw this exciting news:

Announcing a New Era in Alzheimer’s
The Time for Tau Is Now as Phase 3 clinical trials get under way with a second-generation Tau Aggregation Inhibitor (TAI) aimed at halting the progression of Alzheimer’s

· Event: Live Press Conference / Webinar in Conjunction with the 5th Clinical Trials Conference on Alzheimer’s Disease
· Speaker: Professor Claude Wischik, Co-founder and Chairman of TauRx Therapeutics Ltd
· Date: Tuesday, 30th October 2012
· Time: 16:00 – 16:45 Monte Carlo (Central European Time) / 15:00-15:45 London (GMT)
11:00-11:45 am NYC (EST) / 8:00-8:45 am Los Angeles (PST)

To register for the free Webinar by TauRx Chairman Prof Claude Wischik:
http://www.dontforgetalzheimers.com/

You can get video/audio on demand and the pdf slides if you miss the webinar.

Tau, LMTX and Parkinson's

Nearly four years since the last posting and LMTX is back in the newspapers.

The Daily Mail newspaper in the UK is reporting [1] that a drug called LMTX slows the progression of Alzheimer's. It targets tau tangles.

It is speculation at the moment, but this drug might be of use for Parkinson's as well. Tau is implicated in the pathogenesis of PD.

LMTX is similar to methylene blue, which has been posted about on this forum before.

More testing is needed.

Interestingly, US newspapers are reporting the trial as failing. It seems that across the whole cohort there was no improvement. But, in the 15% of the cohort on no other AZ drugs progression was slowed.

Reference:

[1] Alzheimer's pill can slow the process of the disease and can even help recovery | Daily Mail Online

John